P683: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES (TRIAL IN PROGRESS)
W. Jurczak,
A. J. Alencar,
G. S. Guru Murthy,
M. Hoffmann,
J. M. Pagel,
V. Patel,
J. M. Pauff,
P. L. Zinzani,
S. Le Gouill,
A. R. Mato,
L. E. Roeker
Affiliations
W. Jurczak
1 Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
A. J. Alencar
2 Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL
G. S. Guru Murthy
3 Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
M. Hoffmann
4 Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Overland Park, KS
J. M. Pagel
5 Loxo Oncology at Lilly, Stamford, CT, United States of America
V. Patel
5 Loxo Oncology at Lilly, Stamford, CT, United States of America
J. M. Pauff
5 Loxo Oncology at Lilly, Stamford, CT, United States of America
P. L. Zinzani
6 Institute of Hematology Seràgnoli, University of Bologna, Bologna, Italy
S. Le Gouill
7 Institut Curie Hospital, Paris, France
A. R. Mato
8 Memorial Sloan Kettering Cancer Center, New York, NY, United States of America
L. E. Roeker
8 Memorial Sloan Kettering Cancer Center, New York, NY, United States of America
